Advanced search
Publication Cover
HIV Clinical Trials Volume 13, 2012 - Issue 5
Submit an article Journal homepage
49
Views
7
CrossRef citations to date
0
Altmetric
Brief reports

Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study

L. SchneiderInfectious Diseases DepartmentPitié-Salpêtrière Hospital, Paris, France;Pierre et Marie Curie University Paris VI, Paris, FranceCorrespondence[email protected]
,
N. KtorzaInfectious Diseases DepartmentPitié-Salpêtrière Hospital, Paris, France
,
S. FouratiVirology DepartmentPitié-Salpêtrière Hospital, Paris, France;Pierre et Marie Curie University Paris VI, Paris, France
,
L. AssoumouPierre et Marie Curie University Paris VI, Paris, France
,
E. CourbonClinical Pharmacokinetic DepartmentAPHP, Bichat-Claude Bernard Hospital, EA449 Paris VII University, Paris, France
,
F. CabyInfectious Diseases DepartmentPitié-Salpêtrière Hospital, Paris, France;Pierre et Marie Curie University Paris VI, Paris, France
,
C. BlancInfectious Diseases DepartmentPitié-Salpêtrière Hospital, Paris, France
,
M. TindelInfectious Diseases DepartmentPitié-Salpêtrière Hospital, Paris, France
,
R. AgherInfectious Diseases DepartmentPitié-Salpêtrière Hospital, Paris, France
,
A. G. MarcelinVirology DepartmentPitié-Salpêtrière Hospital, Paris, France;Pierre et Marie Curie University Paris VI, Paris, France
,
V. CalvezVirology DepartmentPitié-Salpêtrière Hospital, Paris, France;Pierre et Marie Curie University Paris VI, Paris, France
,
G. PeytavinClinical Pharmacokinetic DepartmentAPHP, Bichat-Claude Bernard Hospital, EA449 Paris VII University, Paris, France
&
C. KatlamaInfectious Diseases DepartmentPitié-Salpêtrière Hospital, Paris, France;Pierre et Marie Curie University Paris VI, Paris, France
 show all
Pages 284-288 | Published online: 06 Jan 2015

REFERENCES

  • Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009; 48(4):484–488.
  • Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15(7):1045–1052.
  • Charpentier C, Roquebert B, Colin C, et al. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS. 2010; 24(17):2651–2656.
  • Jansen-Cilag LTD. Etravirine summary of product chrac-teristics. http://www.ema.europa.eu/docs/en_GB/docu-ment_library/EPAR_-Product_Information/human/000900/WC500034180.pdf.
  • Gazzard B, Duvivier C, Zagler C, et al. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS. 2011; 25(18):2249–2258.
  • Katlama C, Hill A, Van Delft Y, Vingerhoets J. Drug resis-tance after virological failure in the SENSE trial: etra-virine versus efavirenz in treatment-naïve participants. Paper presented at the 13th European AIDS Conference; October 2011; Belgrade, Serbia. PE5.3/4.
  • DeJesus E, Lalezari JP, Osiyemi OO, et al. Pharmacokinet-ics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-in-fected adults. Antivir Ther 2010; 15(5):711–720.
  • HIV genotypic drug resistance interpretation's algorithms, October 2011, version 21. http://www.hivfrenchresistance.org/tab2011-05.html
  • Marcelin AG, Flandre P, Descamps D, et al. Factors associ-ated with virological response to etravirine in non-nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother. 2010; 54(1):72–77.
  • Di Perri G, Green B, Hill A, et al. Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients. Paper presented at the 13th European AIDS Conference; October 2011; Belgrade, Serbia. PS6/2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.